Table 4 ASD Total Score, Item 8, and Item 9 across study timepoints
From: Development and evaluation of the Acromegaly Symptom Diary
Timepoint | n | Mean ± SD | Q1, Median, Q3 | Observed Min, Max | Score Min %, Max % |
|---|---|---|---|---|---|
ASD total score | |||||
Screening Visit | 40 | 14.7 ± 13.7 | 3.5, 10.4, 22.9 | 0.0, 49.4 | 2.5, 0.0 |
Baseline | 31 | 13.0 ± 12.5 | 3.4, 8.6, 22.0 | 0.0, 44.5 | 6.5, 0.0 |
EOT | 42 | 10.9 ± 10.2 | 3.6, 7.8, 18.3 | 0.0, 40.1 | 11.9, 0.0 |
Week 17 | 27 | 12.6 ± 8.2 | 5.4, 13.1, 19.6 | 0.0, 30.7 | 7.4, 0.0 |
Change from screening visit to baseline | 29 | −1.2 ± 5.1 | − 2.9, − 1.1, 0.7 | −15.9, 16.7 | NA |
Change from baseline to EOT | 27 | −2.4 ± 7.0 | −5.0, 0.0, 2.1 | −24.7, 5.3 | NA |
Change from EOT to Week 17 | 25 | 2.1 ± 5.2 | −0.3, 1.6, 5.9 | −8.3, 12.4 | NA |
Sleep difficulties (Item 8) | |||||
Screening visit | 40 | 2.5 ± 2.6 | 0.2, 1.6, 3.9 | 0.0, 9.6 | 22.5, 0.0 |
Baseline | 31 | 2.2 ± 2.7 | 0.3, 1.3, 3.6 | 0.0, 10.0 | 19.4, 3.2 |
EOT | 42 | 2.1 ± 2.5 | 0.0, 1.4, 3.4 | 0.0, 9.0 | 33.3, 0.0 |
Week 17 | 27 | 2.0 ± 2.4 | 0.0, 1.2, 3.2 | 0.0, 9.0 | 25.9, 0.0 |
Change from screening visit to baseline | 29 | − 0.4 ± 0.9 | − 0.7, -0.3, 0.0 | − 2.5, 1.4 | NA |
Change from baseline to EOT | 27 | 0.0 ± 2.4 | − 0.7, 0.1, 0.7 | − 5.4, 6.9 | NA |
Change from EOT to Week 17 | 25 | − 0.2 ± 1.5 | − 0.1, 0.0, 0.4 | − 5.9, 2.1 | NA |
Short-term memory (Item 9) | |||||
Screening visit | 29 | 2.1 ± 2.2 | 0.3, 1.4, 3.1 | 0.0, 8.7 | 17.2, 0.0 |
Baseline | 20 | 2.3 ± 2.6 | 0.1, 1.4, 3.7 | 0.0, 8.5 | 25.0, 0.0 |
EOT | 33 | 1.5 ± 2.0 | 0.0, 1.0, 2.0 | 0.0, 7.7 | 36.4, 0.0 |
Week 17 | 17 | 2.2 ± 2.2 | 0.8, 1.9, 2.7 | 0.0, 9.0 | 23.5, 0.0 |
Change from screening visit to baseline | 19 | 0.1 ± 1.2 | − 0.4, 0.0, 0.3 | − 1.6, 2.9 | NA |
Change from baseline to EOT | 16 | − 0.4 ± 1.3 | − 0.5, 0.0, 0.2 | − 4.6, 0.9 | NA |
Change from EOT to Week 17 | 15 | 0.0 ± 1.5 | − 0.3, 0.0, 0.8 | − 4.0, 3.0 | NA |